PI3K inhibitors in haematological malignancies.
作者信息
Benjamin David J, Prasad Vinay
机构信息
Division of Hematology and Oncology, Department of Medicine, University of California, Irvine, Orange, CA 92868, USA.
Department of Epidemiology and Biostatistics, University of California, San Francisco, San Francisco, CA, USA.
出版信息
Lancet Oncol. 2022 Aug;23(8):e362-e363. doi: 10.1016/S1470-2045(22)00260-1.
Abstract
摘要
相似文献
1
PI3K inhibitors in haematological malignancies.
Lancet Oncol. 2022 Aug;23(8):e362-e363. doi: 10.1016/S1470-2045(22)00260-1.
2
PI3K inhibitors in haematological malignancies.
Lancet Oncol. 2022 Aug;23(8):e365. doi: 10.1016/S1470-2045(22)00332-1.
3
PI3K inhibitors in haematological malignancies.
Lancet Oncol. 2022 Aug;23(8):e364. doi: 10.1016/S1470-2045(22)00300-X.
4
The saga of PI3K inhibitors in haematological malignancies: survival is the ultimate safety endpoint.
Lancet Oncol. 2022 May;23(5):563-566. doi: 10.1016/S1470-2045(22)00200-5. Epub 2022 Apr 14.
5
Synergistic induction of cell death in haematological malignancies by combined phosphoinositide-3-kinase and BET bromodomain inhibition.
Br J Haematol. 2015 Jul;170(2):275-8. doi: 10.1111/bjh.13283. Epub 2015 Jan 12.
6
Targeting the phosphoinositide 3-kinase pathway in hematologic malignancies.
Haematologica. 2014 Jan;99(1):7-18. doi: 10.3324/haematol.2013.087171.
7
PI3K as a target for therapy in haematological malignancies.
Curr Top Microbiol Immunol. 2010;347:169-88. doi: 10.1007/82_2010_71.
8
The role and therapeutic implications of PI3K signaling pathway in cancer.
J Surg Oncol. 2021 Jan;123(1):39-41. doi: 10.1002/jso.26296. Epub 2020 Nov 12.
9
Inhibition of the phosphatidylinositol 3-kinase/mammalian target of rapamycin pathway in hematologic malignancies.
Curr Treat Options Oncol. 2006 Jul;7(4):285-94. doi: 10.1007/s11864-006-0038-1.
10
PI3K Isoform-Selective Inhibitors in Cancer.
Adv Exp Med Biol. 2020;1255:165-173. doi: 10.1007/978-981-15-4494-1_14.
引用本文的文献
1
Mutations: Are They a Relevant Target in Adult Diffuse Gliomas?
Int J Mol Sci. 2025 May 30;26(11):5276. doi: 10.3390/ijms26115276.
2
Risk of Severe Infections Secondary to the Use of Targeted Therapies in Hematological Malignancies.
Cureus. 2024 Jan 10;16(1):e52050. doi: 10.7759/cureus.52050. eCollection 2024 Jan.
3
Risk of Infections Secondary to the Use of Targeted Therapies in Hematological Malignancies.
Life (Basel). 2023 May 28;13(6):1272. doi: 10.3390/life13061272.
Zotero 插件